Browse News
Filter News
Found 124 articles
-
XORTX Welcomes New Member to the Board of Directors - April 08, 2024
4/8/2024
XORTX Therapeutics Inc. welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors.
-
XORTX Announces Participation in Spring 2024 Investor Conferences
4/8/2024
XORTX Therapeutics Inc. announces that Dr. Allen Davidoff, CEO, is scheduled to participate in the following Spring 2024 investor and life sciences investment conferences.
-
XORTX Announces New Clinical Advisory Board Member - March 27, 2024
3/27/2024
XORTX Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease, is pleased to announce that Dr. Ronald Perrone has joined the Company’s Clinical Advisory Board.
-
XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
3/19/2024
XORTX Therapeutics Inc. is pleased to provide a summary of Company’s achievements in 2023 and objectives planned for 2024.
-
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease
1/3/2024
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces submission of a new patent for the treatment of chronic kidney disease.
-
XORTX Welcomes New Member to the Board of Directors
1/2/2024
XORTX Therapeutics Inc. welcomes Mr. Patrick Treanor to the Board of Directors and announces the resignation of Ian Klassen, both effective December 31, 2023.
-
XORTX Meets Nasdaq Continued Listing Requirements - November 29, 2023
11/29/2023
XORTX Therapeutics Inc. announces that it has received a letter of compliance from the Nasdaq Stock Market LLC’s Listing Qualifications Department in connection with Nasdaq Rule 5550 that requires the shares to maintain a minimum bid price of US$1.00 per share.
-
XORTX Announces Share Consolidation
11/8/2023
XORTX Therapeutics Inc. announces that the Company’s board of directors has approved consolidating its common shares on the basis of one post-consolidation Share for every nine pre-consolidation Shares, effective November 9, 2023.
-
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2023
11/2/2023
XORTX Therapeutics Inc. is pleased to announce the presentation of new research findings at the American Society of Nephrology meeting being held November 3, 2023 in Philadelphia.
-
XORTX Announces Results of Special Meeting of Shareholders - October 27, 2023
10/27/2023
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces the results of its special meeting of shareholders held earlier.
-
XORTX Announces Rescheduling of Special Meeting of Shareholders
10/25/2023
XORTX Therapeutics Inc. announces that the special meeting of shareholders that was scheduled for 10:00 a.m. (Calgary time) on October 25, 2023 (the “Meeting”) has been cancelled and will be rescheduled.
-
XORTX Announces Date for Rescheduled Special Meeting of Shareholders
10/25/2023
XORTX Therapeutics Inc. announces that further to its earlier press release, the special meeting of shareholders has been rescheduled to 10:00 a.m. on Friday, October 27, 2023.
-
XORTX Reports that Independent Proxy Firm, ISS, Recommends Shareholders Vote for the Share Consolidation Resolution
10/12/2023
ISS, a leading proxy advisory firm, recommends XORTX Therapeutics Inc.’s shareholders vote FOR the share consolidation resolution, stating that approving the share consolidation will “enhance the long-term growth prospects of the Company by broadening its financing alternatives.”
-
XORTX Calls Special Meeting of Shareholders
10/4/2023
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that the Company has called a special meeting of shareholders for 10:00 a.m. on October 25, 2023.
-
XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2023
9/28/2023
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the acceptance of an abstract submitted to the American Society of Nephrology.
-
XORTX Announces Participation at Upcoming Investor Conferences - September 11, 2023
9/11/2023
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that Dr. Allen Davidoff, President and CEO, is scheduled to participate in the following upcoming investor conferences.
-
XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease
8/29/2023
XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has submitted an Orphan Drug Designation application for XORLO™ to the European Medicines Agency (the “EMA”).
-
XORTX Appoints Chief Financial Officer
8/4/2023
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of James Fairbairn as Chief Financial Officer to replace Amar Keshri who left the Company’s employ effective July 31, 2023.
-
XORTX Announces Results of Annual and Special Meeting of Shareholders
6/29/2023
XORTX Therapeutics Inc. is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held Wednesday, June 28, 2023.
-
XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company’s Upcoming Annual and Special Meeting of Shareholders
6/24/2023
XORTX Therapeutics Inc. would like to remind shareholders that they have until 10:00 a.m. on Monday, June 26, 2023 to vote their shares for the Company’s upcoming annual and special meeting of shareholders to be held on Wednesday, June 28, 2023 at 10:00 a.m.